PAS
NVCR icon

Park Avenue Securities’s NovoCure NVCR Stock Holding History

Park Avenue Securities’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,727
Closed -$201K – 1127
2021
Q3 		$201K Buy
1,727
+658
+62% +$99.5K ﹤0.01% 1002
2021
Q2 		$237K Buy
+1,069
New +$208K 0.01% 929

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Park Avenue Securities's NVCR Position: Q4 2021 in Review

Park Avenue Securities sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 1,727 shares — an estimated $201K sold.

Park Avenue Securities first reported a position in NVCR in Q2 2021 and held it in 2 quarters. The position peaked at $237K in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

  • Park Avenue Securities reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
  • Park Avenue Securities sold 1,727 NovoCure shares in Q4 2021, an estimated $201K.
  • Park Avenue Securities first reported a position in NovoCure in Q2 2021 and held it in 2 quarters.
  • Park Avenue Securities's NovoCure position peaked at $237K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Park Avenue Securities's 13F filing for Q4 2021, filed 8 Apr 2022.